The United States is experiencing an opioid abuse epidemic. In 2015, an estimated 3.8 million people aged 12 and over were misusers of prescription pain relievers 1 and another 828,000 had used heroin. In 2016, there were more than 42,200 opioid overdose deaths, a 28% increase from 2015.
2 Medication-assisted treatment (MAT) is effective, 3 but access to treatment can be challenging, especially for patients in rural locations. The Drug Addiction Treatment Act of 2000 allows physicians who complete 8 hours of training to obtain a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine for opioid use disorder (OUD). In 2016, the Comprehensive Addiction and Recovery Act (CARA) extended this ability to nurse practitioners (NPs) and physician assistants (PAs) who complete 24 hours of training to treat up to 30 patients concurrently in the first year, and 100 patients in subsequent years. 4 Improving overall access to MAT and addressing the difficulties that rural Americans have accessing treatment was a primary goal of this legislation. This research updates the analysis of the 2012 geographic distribution of physicians with a DEA waiver and adds the waiver uptake and geographic distribution of NPs and PAs since the enactment of the CARA legislation.
5

Methods
This research used the DEA Waivered Provider List (December 2017) 6 and the Health and Human Services Administration Area Health Resources File (AHRF). 7 The provider's ZIP code from the DEA Provider File was used to identify the provider's county. The county's Urban Influence Code (UIC) was used to assign each provider into either metropolitan (also referred to as urban) or 1 of 3 rural geographic categories (micropolitan adjacent to metropolitan, micropolitan not adjacent to metropolitan, and small and remote rural). UICs designate counties based on the size of their largest urban core and adjacency to a metropolitan county. The AHRF also contains the number of licensed NPs and PAs in each county. The University of Washington's Institutional Review Board determined this study was exempt from human subjects' research requirements.
Results
The availability of a physician with a DEA waiver to prescribe office-based MAT has increased across all geographic categories since 2012. 5 This percentage increase was greater in rural counties (10.7%) than urban counties (4.4%), with micropolitan counties not adjacent to a metropolitan county having the greatest increase (14.2%). Although this is the case, the majority of rural counties (56.3%) still lack a waivered physician (down from 67.1% in 2012), while only 23.2% of urban counties lack a physician provider (Table 1) . Overall, more than half (56.0%) of US counties now have a physician with a DEA waiver (Figure 1 ), up from 46.6% in 2012. The inclusion of NPs and PAs in the MAT workforce has modestly increased the provider supply across the country, with 45.9% and 24.5% of urban counties having a waivered NP or PA, respectively, and 13.8% and 4.6% of rural counties having a waivered NP or PA, respectively.
The increase in the number of waivered providers is also reflected in the changes in the provider-topopulation ratios since 2012. In urban counties, the number of waivered physicians per 100,000 population increased from 6.3 to 11.0; furthermore, adding NPs and PAs to this provider workforce raised the current urban provider-to-population ratio to 12.4. In rural counties, the number of waivered physicians per 100,000 population nearly doubled in all geographic categories. When waivered NPs and PAs are included, the provider-topopulation ratio more than doubled in micropolitan, adjacent to metropolitan counties (3.3 to 7.2); micropolitan, not adjacent to metropolitan counties (4.2 to 10.1); and in small and remote rural counties (3.1 to 7.8).
Almost 20 million US residents (7.1%) live in a county without any type of waivered provider, with the majority (69.7%) of them being in rural counties. Compared with only 2.2% of metropolitan residents, almost a third of the US rural population (29.8%) lives in a county without a provider with a DEA waiver.
After approximately 1 year of eligibility, 3,534 NPs (1.7% of eligible NPs given state laws) 8, 9 and 912 PAs (0.8% of eligible PAs given state laws)
10 from 883 different counties had obtained a DEA waiver allowing them to prescribe buprenorphine for OUD. A larger percentage of newly waivered NPs (14.2%) and PAs (14.4%) were located in rural counties compared to their physician counterparts (8.9%). Most waivered NPs and PAs were in counties that also had a waivered physician, but in 56 counties (43 rural) with a cumulative population of 1.5 million residents, NPs and PAs expanded treatment availability and were the only available waivered providers. In 827 counties (269 rural counties), NPs and PAs are waivered in addition to waivered physicians.
Discussion
Despite an increase in the number of providers waivered to deliver office-based MAT, a large percentage of US counties still have no waivered providers, and a substantial disparity still exists between rural and urban counties. Rural communities experience both greater barriers to receiving care and higher opioid overdose rates than their urban counterparts. 11, 12 While lack of treatment access is clear in counties with no waivered providers, access challenges may also be significant in many counties that have a provider given the tremendous need. 13 Additionally, many physicians with a waiver have reported not using it, 14 further diminishing access. If a nonprescribing waivered physician is from one of the 442 counties that have only 1 provider (24.3% of counties that have a waivered provider), that county's population is at risk of having no access to MAT. It is not known how many waivered NPs or PAs are not actively prescribing.
Extending the ability to offer MAT to NPs and PAs has the potential to improve treatment access across the country, especially in rural counties where access is most limited. Only 1.6% of waivered NPs and PAs expanded access in counties that previously had no providers, while 98.4% became waivered in counties that already had at least 1 waivered provider. It is possible this is due to scope DEA = Drug Enforcement Administration; UIC = urban influence code; NP = nurse practitioner; PA = physician assistant. a Counties with an urban core with a population of at least 50,000, UIC 1-2. b Counties that are geographically adjacent to a metropolitan area whose largest town/urban cluster has 10,000-49,999 residents, UIC 3-7. c Counties that are not adjacent to a metropolitan area and whose largest town/urban cluster has 10,000-49,999 residents, UIC 8. d Counties whose largest town has fewer than 10,000 residents regardless of proximity to a micropolitan county, UIC 9-12. Notes: Counties were classified as urban or into 1 of 3 categories of rural using the US Department of Agriculture UIC. Rows' percentages may not sum to 100% due to rounding.
of practice regulations in some states that limit the ability for NPs to practice independently of another waivered provider, or even obtain the initial waiver. 8, 9 The CARA legislation also increased the maximum number of patients that waivered physicians could treat concurrently to 275 for physicians who met certain criteria, but eligibility requirements may be difficult for rural physicians to meet. CARA legislation does not permit NPs and PAs to obtain the 275-patient waiver.
This study has several limitations. These results indicate counties where at least 1 provider with a DEA waiver is located, but they do not adjust for patient need or availability of treatment slots. Additionally, DEA data do not show where waivered physicians are not prescribing. Therefore, the data presented here paint a best case scenario of MAT availability and may overestimate supply. Furthermore, the CARA legislation had only been in effect for 1 year at the time of data collection; consequently, these results show the initial numbers of NPs and PAs who have obtained their waiver to prescribe buprenorphine for the treatment of OUD. Future research is needed to fully understand the impact that expanding waiver privileges to NPs and PAs will have on the buprenorphine provider workforce. Finally, providers were mapped to a county based on their DEA ZIP code; because some ZIP codes cross county lines, it is possible that physicians within those ZIP codes were mapped to the incorrect adjacent county. ZIP codes are assigned to the county where the majority of the ZIP code population is located.
Increasing the number of providers with a DEA waiver could improve access to treatment, especially in rural areas. However, given that many physicians with a DEA waiver report barriers to providing MAT, 15 developing strategies to overcome common barriers is essential in order to encourage all types of providers to prescribe. Addressing these barriers should improve access to treatment for patients and help curb the drastic increases in lethal unintentional overdoses.
